课题基金 / 基金详情

Omics Technology facility

Omics Technology facility
组学技术设施
批准号：
10487274
负责人：
Liang Cao
金额：
$17.01万
依托单位：
DIVISION OF BASIC SCIENCES - NCI
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10487274
关键词：
ATAC-seqAlgorithmsAnnual ReportsAreaBioinformaticsBiologicalBiological AssayBiologyCCRCellsClassificationCommunicationCommunitiesComputational BiologyCooperative Research and Development AgreementDNA analysisDNA sequencingDataEnhancersEpigenetic ProcessFoundationsFundingGene RearrangementGeneticGenomeGoalsImageImmunogenomicsIndustrializationIntentionLaboratoriesLearningMachine LearningMass Spectrum AnalysisMolecular ProfilingMolecular TargetPreparationProteomicsProtocols documentationResearchResearch PersonnelResourcesSequence AnalysisStructureTechnical ExpertiseTechnologyTrainingUnited States National Institutes of HealthWorkbasebiomarker developmentclinical biomarkersconvolutional neural networkgenome sequencinginnovationmembernew technologyoperationscreeningsingle-cell RNA sequencingtooltranscriptome sequencingtumorwhole genome

项目摘要

项目成果

Liang Cao的其他基金

相似基金

相关文献

中文摘要
翻译
核心将于2021年10月正式开始运营。为了准备合并，我进行了各种活动，包括：1。与GB的调查人员建立正式沟通，以确定科学和研究技术需求，以及基金将学习和利用的科学和技术专门知识。2.探索各种技术平台，以便立即适应。3.开始培训现有工作人员，以操作新的OMICS设施。预计2022年年度报告中将有更重要的项目摘要。
英文摘要
The core will officially begin operations in Oct. 2021. In preparation to the merge, I have conducted various activities including: 1. Established formal communications with the investigators in the GB to identify scientific and research technological needs, as well as their scientific and technical expertise for which the Facility would learn and utilize. 2. Exploring various technology platforms for immediate adaptation. 3. Initiating the training of the current staff for the operation of the new OMICS Facility. More significant project summary is expected in the annual report of 2022.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma
Molecular Pathogenic Mechanism of Rhabdomyosarcoma
Biomarker Investigations for Clinical Trials
Omics Technology facility
海外基金